Why Chris Kourtis just bought CSL and ResMed
Joshua PeachMarkets reporter
A true contrarian investor, Chris Kourtis can find himself sounding a lot like a bull when in the company of bears, and there’s a lot to be bearish about at the moment.
“When you put it in the melting pot very slow global growth, very high and sticky stagflation against a backdrop of the geopolitical environment, it’s a time to be cautious,” he tells The Australian Financial Review.
Loading...
Joshua Peach is a Markets Reporter at The Australian Financial Review Email Joshua at joshua.peach@nine.com.au
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Equity markets
Fetching latest articles